Physician profile
Benjamin A Debski
NPI 1023558228
$1,629.75
in general payments reported to CMS, 2019-2025
22 companies · $424 in 2025
The $424 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $139 · 2022: $251 · 2023: $393 · 2024: $423 · 2025: $424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,239.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $670.68 | 2021-2025 | |
| Axsome Therapeutics, INC. | $319.88 | 2023-2025 | Sunosi, Symbravo |
| Pfizer INC. | $132.34 | 2022-2025 | |
| Lilly USA, LLC | $64.06 | 2021-2024 | Zepbound, Mounjaro |
| Idorsia Pharmaceuticals US INC | $52.34 | 2022-2024 | Quviviq |
| Corcept Therapeutics | $41.24 | 2023 | Korlym |
| Jazz Pharmaceuticals INC. | $40.75 | 2021 | |
| Hikma Pharmaceuticals USA | $40.21 | 2023-2025 | Ryaltris, Kloxxado, Mitigare |
| Teva Pharmaceuticals USA, INC. | $39.46 | 2024 | Austedo Xr |
| Exact Sciences Corporation | $36.09 | 2024 | Cologuard Collection Kit |
| Alexion Pharmaceuticals, INC. | $21.84 | 2024 | Strensiq |
| Genzyme Corporation | $20.65 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.30 | 2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $15.88 | 2022 | |
| Phadia US INC. | $15.84 | 2024 | Immunocap |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $15.61 | 2022 | |
| Azurity Pharmaceuticals, INC. | $15.59 | 2023 | Adthyza |
| Astrazeneca Pharmaceuticals LP | $14.40 | 2025 | Airsupra |
| Nabriva Therapeutics, Plc | $13.99 | 2022 | |
| Acella Pharmaceuticals, LLC | $13.34 | 2024 | NP Thyroid 60 |
| Astellas Pharma US INC | $13.16 | 2024 | Veozah |
| Otsuka America Pharmaceutical, INC. | $13.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Debski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.